Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you study drug mechanisms, cancer biology, or diabetes therapeutics, NIH is funding urgent research on whether GLP-1 drugs increase or decrease cancer risk—a gap with real clinical stakes.
Report stale or inaccurate summary
What this is
This R21 grant funds research into the biological mechanisms by which incretin mimetic drugs—increasingly used for diabetes and weight loss—impact cancer risk. Applicants should propose preclinical laboratory studies or patient-based observational/mechanistic research (clinical trials are not allowed). The field lacks clarity on whether these agents uniformly increase cancer risk, decrease it, or have mixed effects depending on cancer type and patient population. This is an opportunity to fill that evidence gap and attract scientific talent to an understudied but clinically urgent question.
Who can apply
Broad eligibility including nonprofits (501(c)(3) and non-501(c)(3)), universities, small businesses, for-profit companies (except large for-profits), state/local governments, and tribal organizations. Solo researchers should partner with or be embedded in an eligible institution; independent applicants must work through an institutional fiscal sponsor.
Eligible applicant types
- Public housing authorities/Indian housing authorities
- Independent school districts
- Native American tribal governments (Federally recognized)
- Public and State controlled institutions of higher education
- State governments
- City or township governments
- Small businesses
- For profit organizations other than small businesses
- County governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Private institutions of higher education
- Special district governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Full description — from the agency
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Topics: incretin mimetics · glp-1 agonists · cancer mechanism · drug safety · obesity-related cancers · preclinical research
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.